Moleculin Biotech, INC 8-K filings

Moleculin Biotech, Inc. announced it is furnishing its July 2025 Investor Presentation as an exhibit to its latest 8-K filing.

Moleculin Biotech, Inc. announced receipt of a Notice of Intent to Grant a new European patent for its drug candidate Annamycin, enhancing its intellectual property portfolio and market position.

A late-stage pharmaceutical company has appointed a seasoned industry veteran as a Strategic Advisor to accelerate partnerships, particularly ahead of key clinical trial data unblinding for its lead cancer drug.

Moleculin Biotech, Inc. has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC to sell up to $6.5 million of its common stock for working capital and general corporate purposes.

Moleculin Biotech, Inc. announced the approval of its pivotal Phase 2B/3 MIRACLE clinical trial for Annamycin in relapsed/refractory Acute Myeloid Leukemia in Georgia, alongside an update on enrollment and future site expansion plans.

Moleculin Biotech, Inc. has received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share, initiating a 180-day compliance period.

Moleculin Biotech, Inc. has successfully priced a public offering, raising approximately $5.9 million in gross proceeds to advance its clinical and preclinical drug development programs.

Moleculin Biotech, Inc. announced positive feedback from the FDA on its Initial Pediatric Study Plan for Annamycin, allowing for a single pediatric approval study in children as young as 6 months with relapsed/refractory acute myeloid leukemia.

Moleculin Biotech, Inc. announced it hosted a virtual Key Opinion Leader (KOL) event on June 5, 2025, focusing on Soft Tissue Sarcoma (STS) Lung Metastases.

Moleculin Biotech, Inc. announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial (MB-107) evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases, demonstrating promising survival rates and no cardiotoxicity.

Moleculin Biotech, Inc. has been notified by Nasdaq of non-compliance with listing rules due to failing to meet the minimum stockholders' equity requirement, initiating a process to regain compliance.

Moleculin Biotech announces its Q1 2025 financial results and provides an update on its clinical programs, including the Phase 3 MIRACLE trial for Annamycin in R/R AML.

Moleculin Biotech's Phase 3 MIRACLE trial for Annamycin in R/R AML receives EMA approval, expanding the trial to nine additional EU countries.

Moleculin Biotech's Special Meeting of Stockholders was cancelled on May 9, 2025, due to the absence of a quorum, despite approximately 70% of voted shares being in favor of the motion.

Moleculin Biotech will release its Q1 2025 financial results on May 13, 2025, followed by a conference call on May 14, 2025, to discuss the results and provide an operational update.

Moleculin Biotech announces that the World Health Organization has approved 'naxtarubicin' as the International Nonproprietary Name (INN) for its drug candidate Annamycin.

Moleculin Biotech announces the grant of two new U.S. patents related to Annamycin, further strengthening its intellectual property position.

Moleculin Biotech presented data at the AACR Annual Meeting 2025, showcasing Annamycin's potential in treating pancreatic cancer and other solid tumors through synergistic combinations with existing therapies.

Moleculin Biotech's Special Meeting of Stockholders has been adjourned for a second time due to the absence of a quorum, now rescheduled for May 9, 2025.

Moleculin Biotech, Inc. released a corporate presentation on its website on April 21, 2025.

Moleculin Biotech announces that an abstract regarding its next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Moleculin Biotech's Special Meeting of Stockholders was adjourned to April 25, 2025, due to the absence of a quorum.

Moleculin Biotech has initiated its Phase 3 pivotal MIRACLE trial, dosing the first patient to evaluate Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).

Moleculin Biotech releases an updated corporate presentation on its website, providing insights into the company's current status and future plans.

Moleculin Biotech reports its full year 2024 financial results and provides a corporate update, highlighting progress in its Phase 3 MIRACLE trial and expected data readouts.

Moleculin Biotech announces a Notice of Intent to Grant for a European patent application related to its liposomal Annamycin formulation, enhancing global exclusivity for this potential cancer treatment.

Moleculin Biotech secures $3.5 million through a registered direct offering and private placement to fund working capital and general corporate purposes.

Moleculin Biotech incentivizes warrant holders to exercise existing warrants, generating approximately $5.8 million in gross proceeds and issuing new warrants for future common stock purchases.

Moleculin Biotech announces positive FDA feedback allowing for a reduced size in its Phase 3 MIRACLE trial for Annamycin in R/R AML, potentially accelerating the timeline for new drug approval.

Moleculin Biotech has received its first European regulatory approval to begin recruiting for its Phase 3 MIRACLE trial evaluating Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).